Vimentin Antibody - #BF0071

(6)   (7)  
製品: Vimentin Antibody
カタログ: BF0071
タンパク質の説明: Mouse monoclonal antibody to Vimentin
アプリケーション: WB IHC ELISA
Cited expt.: WB, IHC
反応性: Human, Mouse, Rat, Monkey
分子量: 54kDa; 54kD(Calculated).
ユニプロット: P08670
RRID: AB_2833686

類似製品を見る>>

   サイズ 価格 在庫状況
 50ul $250 在庫あり
 100ul $350 在庫あり
 200ul $450 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Mouse
アプリケーション:
ELISA 1:10000, WB 1:500-1:2000, IHC 1:200-1:1000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat,Monkey
クローナリティ:
Monoclonal [AFB1662]
特異性:
Vimentin antibody detects endogenous levels of total Vimentin.
RRID:
AB_2833686
引用形式: Affinity Biosciences Cat# BF0071, RRID:AB_2833686.
コンジュゲート:
Unconjugated.
精製:
Affinity-chromatography.
保存:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

CTRCT30; Epididymis luminal protein 113; FLJ36605; HEL113; VIM; VIME_HUMAN; Vimentin;

免疫原

免疫原:

Purified recombinant fragment of human Vimentin expressed in E. Coli.

Uniprot:

P08670(VIME_HUMAN) >>Visit HPA database.

遺伝子(ID):
VIM(7431)
発現特異性:
P08670 VIME_HUMAN:

Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.

タンパク質の説明:
Vimentin, also know as VIM. It is the major subunit protein of the intermediate filaments of mesenchymal cells. It is believed to be involved with the intracellular transport of proteins between the nucleus and plasma membrane. Vimentin has been implicated to be involved in the rate of steroid synthesis via its role as a storage network for steroidogenic cholesterol containing lipid droplets.
タンパク質配列:
MSTRSVSSSSYRRMFGGPGTASRPSSSRSYVTTSTRTYSLGSALRPSTSRSLYASSPGGVYATRSSAVRLRSSVPGVRLLQDSVDFSLADAINTEFKNTRTNEKVELQELNDRFANYIDKVRFLEQQNKILLAELEQLKGQGKSRLGDLYEEEMRELRRQVDQLTNDKARVEVERDNLAEDIMRLREKLQEEMLQREEAENTLQSFRQDVDNASLARLDLERKVESLQEEIAFLKKLHEEEIQELQAQIQEQHVQIDVDVSKPDLTAALRDVRQQYESVAAKNLQEAEEWYKSKFADLSEAANRNNDALRQAKQESTEYRRQVQSLTCEVDALKGTNESLERQMREMEENFAVEAANYQDTIGRLQDEIQNMKEEMARHLREYQDLLNVKMALDIEIATYRKLLEGEESRISLPLPNFSSLNLRETNLDSLPLVDTHSKRTLLIKTVETRDGQVINETSQHHDDLE

研究背景

機能:

Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally.

Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2.

PTMs:

Filament disassembly during mitosis is promoted by phosphorylation at Ser-55 as well as by nestin (By similarity). One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is enhanced during cell division, at which time vimentin filaments are significantly reorganized. Phosphorylation by PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by CDK5 during neutrophil secretion in the cytoplasm. Phosphorylated by STK33. Phosphorylated on tyrosine residues by SRMS.

O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status.

S-nitrosylation is induced by interferon-gamma and oxidatively-modified low-densitity lipoprotein (LDL(ox)) possibly implicating the iNOS-S100A8/9 transnitrosylase complex.

細胞の位置付け:

Cytoplasm. Cytoplasm>Cytoskeleton. Nucleus matrix.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.

タンパク質ファミリー:

The central alpha-helical coiled-coil IF rod domain mediates elementary homodimerization.

The [IL]-x-C-x-x-[DE] motif is a proposed target motif for cysteine S-nitrosylation mediated by the iNOS-S100A8/A9 transnitrosylase complex.

Belongs to the intermediate filament family.

研究領域

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

参考文献

1). Palmitic acid-modified bovine serum albumin nanoparticles target scavenger receptor-A on activated macrophages to treat rheumatoid arthritis. Biomaterials, 2020 (PubMed: 32781326) [IF=12.8]
2). Psychologic Stress Drives Progression of Malignant Tumors via DRD2/HIF1α Signaling. CANCER RESEARCH, 2021 (PubMed: 34321238) [IF=12.5]

Application: IF/ICC    Species: mouse    Sample: tumor cells

Fig. 2. |DRD2 overexpression promotes the metastasis, invasion, tube formation, and cloning formation of tumor cells.K and L, Effect of DRD2 on the expression of E-cadherin and vimentin detected by IF. Each experiment was performed in triplicate. Results are shown as means ± SD, *, P < 0.05; **, P < 0.01.

Application: WB    Species: mouse    Sample: dopamine-treated melanoma cells

Fig. 6. |TFP inhibits EMT of melanoma cells.C, Effect of TFP on the EMT markers (E-cadherin and vimentin) in dopamine-treated melanoma cells.
3). Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway. EBioMedicine, 2018 (PubMed: 30396856) [IF=9.7]

Application: IHC    Species: mouse    Sample: tumor

Fig. 4. |Sal inhibited migration and invasion and reversed the changes in EMT biomarkers. (A–B) Cell migration was measured after treatment with various drugs for 48 h. (C–D)Representative images of Transwell cell invasion assays were obtained at 200× magnification. (E–F) Double immunofluorescence staining for E-cadherin and vimentin after treated with Sal. (G-H) The expression levels of HIF-1α in tumor tissues of subcutaneously transplanted tumor mice. Error bars represent the standard deviation of experiments performed intriplicate (*P b .05, **P b .01).

Application: IF/ICC    Species: human    Sample: HCC cells

Fig. 4. |Sal inhibited migration and invasion and reversed the changes in EMT biomarkers. (A–B) Cell migration was measured after treatment with various drugs for 48 h. (C–D)Representative images of Transwell cell invasion assays were obtained at 200× magnification. (E–F) Double immunofluorescence staining for E-cadherin and vimentin after treated with Sal. (G-H) The expression levels of HIF-1α in tumor tissues of subcutaneously transplanted tumor mice. Error bars represent the standard deviation of experiments performed intriplicate (*P b .05, **P b .01).
4). Up-regulation of miR-20a by HPV16 E6 exerts growth-promoting effects by targeting PDCD6 in cervical carcinoma cells. Biomedicine & Pharmacotherapy, 2018 (PubMed: 29710555) [IF=6.9]
5). Selpercatinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway. Biochemical pharmacology, 2024 (PubMed: 38762147) [IF=5.3]
6). Upregulation of Translationally Controlled Tumor Protein Is Associated With Cervical Cancer Progression. Frontiers in Molecular Biosciences, 2021 (PubMed: 34589516) [IF=5.0]

Application: WB    Species: Human    Sample:

FIGURE 5 Identification of key proteins involved in PI3K/AKT/mTOR pathway over-activation, apoptosis suppression, EMT, and p53 degradation in cancerous tissues of cervical cancer patients, in comparison with the paracancerous tissues. (A) WB images that are representative of all samples tested. (B) Densitometry quantification of the WB results from the experiment performed in A. The ratio of BAX:BCL2 is calculated to highlight the apoptosis activity.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.